Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay

International Journal of Clinical Oncology

Volumn 20, Issue 5, 2015, Pages 878-890

  Wang, Hye young ^a   Ahn, Sungwoo ^b   Kim, Sunghyun ^b,c   Park, Sunyoung ^b   Jung, Dongju ^d   Park, Sangjung ^e   Han, Hyunju ^f   Sohn, JooHyuk ^g   Kim, SeungIl ^h   Lee, Hyeyoung ^b  

^a M D Inc Wonju Eco Environmental Technology Center   (South Korea)

^b Yonsei University Wonju   (South Korea)

^c Yonsei University   (South Korea)

^d Hoseo University   (South Korea)

^e Daegu Haany University   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h Yonsei University College of Medicine   (South Korea)

Author keywords

Anti tumor treatment; Breast cancer; Circulating tumor cells (CTCs); Molecular diagnosis; RT qPCR

Indexed keywords

ANTINEOPLASTIC AGENT; CELL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; KI 67 ANTIGEN; TELOMERASE REVERSE TRANSCRIPTASE; VIMENTIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CIRCULATING TUMOR CELL; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BLOOD; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; TUMOR EMBOLISM; YOUNG ADULT;

ADULT; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84942980741     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-015-0798-3     Document Type: Article

References (24)

1. Coughlin SS, Ekwueme DU (2009) Breast cancer as a global health concern. Cancer Epidemiol 33:315–318
2. Breast Cancer Statistics. http://www.cancerresearchuk.org/. Accessed 23 May 2013
3. Ignatiadis M, Georgoulias V, Mavroudis D (2008) Micrometastatic disease in breast cancer: clinical implications. Eur J Cancer 44:2726–2736
4. Slade MJ, Coombes RC (2007) The clinical significance of disseminated tumor cells in breast cancer. Nat Clin Pract Oncol 4:30–41
5. Alunni-Fabbroni M, Sandri MT (2010) Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods 50:289–297
6. Ignatiadis M, Georgoulias V, Mavroudis D (2008) Circulating tumor cells in breast cancer. Curr Opin Obstet Gynecol 20:55–60
7. Parikh RR, Yang Q, Higgins SA et al (2008) Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. Int J Radiat Oncol Biol Phys 70:35–42
8. Elder EE, Xu D, Höög A et al (2003) KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod Pathol 16:246–255
9. Domagala W, Lasota J, Dukowicz A et al (1990) Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am J Pathol 137:1299–1304
10. Radhika K, Prayaga AK (2010) Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry. Indian J Cancer 47:148–150
11. Moretti E, Desmedt C, Biagioni C et al (2013) TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. Future Oncol 9:1477–1487
12. Swennenhuis JF, Reumers J, Thys K et al (2013) Efficiency of whole genome amplification of single circulating tumor cells enriched by Cell Search and sorted by FACS. Genome Med 5:106
13. Van der Auwera I, Peeters D, Benoy IH et al (2010) Circulating tumour cell detection: a direct comparison between the Cell Search System, the Adna test and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 102:276–284
14. ®): the dilemma of a concept suspended in Limbo. Onco Targets Ther 7:619–625
15. Müller V, Riethdorf S, Rack B et al (2012) Prognostic impact of circulating tumor cells assessed with the Cell Search System™ and Adna Test Breast™ in metastatic breast cancer patients: the detect study. Breast Cancer Res 14:R118
16. Andreopoulou E, Yang LY, Rangel KM et al (2012) Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen Adna Test Breast Cancer Select/Detect™ versus Veridex Cell Search™ system. Int J Cancer 130:1590–1597
17. Amadori A, Rossi E, Zamarchi R et al (2009) Circulating and disseminated tumor cells in the clinical management of breast cancer patients: unanswered questions. Oncology 76:375–386
18. Wang HY, Ahn S, Kim S et al (2014) Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy. Exp Mol Pathol 97:445–452
19. Hong B, Zu Y (2013) Detecting circulating tumor cells: current challenges and new trends. Theranostics 3:377–394
20. Riethdorf S, Fritsche H, Müller V et al (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cell search system. Clin Cancer Res 13:920–928
21. Ntoulia M, Kaklamanis L, Valavanis C et al (2006) HER-2 DNA quantification of paraffin-embedded breast carcinomas with Light Cycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization. Clin Biochem 39:942–946
22. Fehm T, Müller V, Aktas B et al (2010) HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 124:403–412
23. Maestro LM, Sastre J, Rafael SB et al (2009) Circulating tumor cells in solid tumor in metastatic and localized stages. Anticancer Res 29:4839–4843
24. Costelloe CM, Chuang HH, Madewell JE et al (2010) Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer 1:80–92